The prognostic significance of long noncoding RNAs in non-small cell lung cancer: a meta-analysis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1523 views | HTML 1846 views | ?
Wei Jing1,*, Nandi Li1,*, Yingchao Wang1, Xuefang Liu1, Shengjun Liao1, Hongyan Chai1 and Jiancheng Tu1
1 Department of Laboratory Medicine, Clinical Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, China
* These authors have contributed equally to this work
Jiancheng Tu, email:
Hongyan Chai, email:
Keywords: non-small cell lung cancer; long noncoding RNAs; prognosis; lymph node metastasis; meta-analysis
Received: November 01, 2016 Accepted: December 08, 2016 Published: December 15, 2016
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The overall 5-year survival rate of patients is extremely low and to find a new marker is urgently needed. Numerous studies indicate that long noncoding RNAs (lncRNAs) abnormally express in cancers. However, the results have been disputed, especially in the aspects of tumor prognosis. Therefore, we performed this meta-analysis to systematically summarize the relationship between lncRNAs expression and NSCLC. A total of 34 eligible studies including 30 on overall survival, 10 on progression-free survival and 23 on clinicopathological features were identified from the databases. Our results indicated that the levels of lncRNAs were associated with the overall survival (OS; hazard ratios [HR], 1.43; 95% confidence interval [95% CI], 1.17-1.76; P < 0.001). However, there was no relationship between lncRNAs and progression-free survival (PFS; hazard ratios [HR], 1.55; 95% confidence interval [95% CI], 0.91-2.63; P = 0.11). Moreover, lncRNAs were related to lymph node metastasis (odds ratios [OR], 1.70; 95% confidence interval [95% CI], 1.03-2.80; P = 0.04), while no association was observed with other characteristics. In conclusion, our present meta-analysis indicated that lncRNAs transcription levels may serve as a promising marker for prognosis of patients with NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.